Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis

Deucravacitinib may confer an additive effect in some patients with psoriasis and psoriatic arthritis whose disease is not adequately controlled on systemic monotherapy. This study found that deucravacitinib proved to be a safe adjunctive therapy to patients with refractory disease.